Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
Pulmonary Emphysema
About this trial
This is an interventional treatment trial for Pulmonary Emphysema focused on measuring emphysema, pulmonary emphysema, COPD, COLD, chronic obstructive pulmonary disease
Eligibility Criteria
Inclusion Criteria include: Clinical diagnosis of advanced emphysema Age > 18 years at the time of initial presentation Clinically significant dyspnea (MRC Dyspnea >/= 2) Laboratory tests within protocol-specified ranges Pulmonary function tests Exclusion Criteria include: Alpha-1 protease inhibitor deficiency verified by a serum level of <80mg% or knowledge of PI*ZZ genotype Tobacco use within 16 weeks of the initial clinic visit Body mass index < 15 kg/m2 or > 35 kg/m2 Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis Allergy to fish or pork products or sensitivity to tetracycline FEV1 <20% predicted with DLCO <20% predicted or homogeneous disease
Sites / Locations
- St. Antonius Ziekenhuis
Arms of the Study
Arm 1
Experimental
single
BLVR Treatment